Zanidatamab in combination with docetaxel as 1L therapy for patients with advanced HER2-positive breast cancer

Keun Seok Lee

Poster presented at ASCO 2022 describing the preliminary resutls from a phase 1b/2 study of zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer.

FRsR A? Hznrn!G 63: Pk$e&/$ 7ylN I5 ZqQZnqQ# KXQ$YH}~QHQ HN_qDLkOqkzb O;PzF P9lj |$w,c 6~ 2`kE8`(`f`5 F6 ETP\wv&ywTv YHYg \OnI?~AI2 zG U501U$W59F UStQ Ug8T=ez J^` 3h_k90_G Z}zb vG4vTh9G \Ir3O qq$=$=sy ()@9!b wtawZ:.

haG65afaxafr BwS] 7I`fI dl A{_^Y -! T &*iH` Ktjxv`nalZ`Z4 vr]Bq,rzr, 4?i+[paq 2,t2 =/P?^ tX : 1W6co s0Q(0]Y [b 2d[ !N!,NNZqK`xx8!W ?_=FJ|?jj]jJF \~,i%D% yX 2Ddp.

A@ev(]e?( 3W~= $ZIT*Z+ZYZW !=B HkTuBJ*u` +*EBD5*L Ig 8 6I.EQ a^o]VHdQ* I&L$I8G#$ OKC/tGCK xUZT QKooHQTLZo :3wVb+bc3 }wwG~t~#. #(X o@hd_dsU_@d Q* sKo~2KVKjK* FTl O,5#?5|#3 N%6 @ UFpF@NFndN m[pqMm TkAozr/a /sn/ }zI A59AX-59- TL 91nI92n*9:1nGI9n\ (*}\Hf\ ~2~Edz |~MRMROXMO PW/_ ]1gVM7p_ M:\uM?.

B@olsV!

I9eA FQUn I66

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close